0RD1.LSE Camurus AB

Healthcare Commercial Services & Supplies London Exchange
653.28 SEK
Close of Jul 18, 2026
433.00 707.50
Market cap
SEK 25.1B
P/E
-
P/B
-
ROE
16.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 0RD1.LSE undervalued?

Graham number

The Graham number of Camurus AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Camurus AB fundamental analysis

No fundamental analysis for Camurus AB yet.

Camurus AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and…

Full company profile